Lexeo Therapeutics, Inc. (LXEO): Cash & Equivalents
$63.00M
As of 2025-12-31
$92.83M
As of 2026-06-30
-6.6%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $63.00M | +79.9% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $35.01M | -71.2% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $121.47M | +57.1% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $77.33M | n/a | 2024-03-11, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | 2025-12-31 | $63.00M | +79.9% |
| Tectonic Therapeutic, Inc. (TECX) | 2025-12-31 | $253.80M | +79.7% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
| Coherus Oncology, Inc. (CHRS) | 2025-12-31 | $88.88M | -29.5% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
| Alector, Inc. (ALEC) | 2025-12-31 | $65.80M | +99.3% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $91.14M | -36.7% |
| Kyverna Therapeutics, Inc. (KYTX) | 2025-12-31 | $124.09M | +28.4% |
Compare LXEO, TECX, IVVD, CHRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗